Thor-707 il-2
WebAug 9, 2024 · In mice, administration of THOR-707 results in large-scale activation and amplification of CD8 + T cells and NK cells, without Treg expansion characteristic of IL-2. … WebBackground SAR444245 (THOR-707) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to block the alpha …
Thor-707 il-2
Did you know?
WebThe company’s lead immuno-oncology (IO) product candidate, THOR-707, a variant of interleukin-2 (IL-2), is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded based on important discoveries at The Scripps Research Institute. Web无独有偶，同样是IL-2受体激动剂的THOR-707，也采取了相近策略。在IL-2蛋白上定向加入PEG修饰，不但提高THOR-707稳定性，而且让它无法与α链结合。 2024年12月，赛诺菲以25亿美元收购Synthorx获得THOR-707，加速进军IL-2赛道。
WebOct 29, 2024 · The pharmas are planning a Phase II trial of Sanofi’s non-alpha IL-2 candidate THOR-707 in combination or sequenced administration with Keytruda for various can ... WebOct 29, 2024 · About THOR-707. THOR-707 has the potential to be a best-in-class IL-2 therapeutic for the treatment of many types of malignancies and may demonstrate …
WebThe objectives of the dose escalation phase are to identify the recommended phase 2 dose (RP2D) of THOR-707 as a monotherapy (Part 1) and in combination with a checkpoint inhibitor (Part 2); to evaluate safety/tolerability of THOR-707; to evaluate anti-tumor activity of THOR-707; to evaluate pharmacokinetics of THOR-707; and to evaluate various … WebMay 15, 2024 · The company’s lead product candidate, THOR-707, a variant of IL-2, is in development in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor.
WebNov 3, 2024 · The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years and older with advanced and metastatic gastrointestinal cancer.
WebJul 1, 2024 · Abstract. THOR-707 (SAR444245) is a recombinant human IL-2 molecule that includes a PEG moiety irreversibly bound to a novel amino acid via click chemistry to … red lights by skzWebOct 30, 2024 · About THOR-707. THOR-707 has the potential to be a best-in-class IL-2 therapeutic for the treatment of many types of malignancies and may demonstrate improved pharmacology allowing for less frequent dosing. In pre-clinical experiments, THOR-707 shows striking synergy with anti-PD-1 therapeutics. richard harigWebTHOR-707 was designed to have advantages of current IL-2 therapies. THOR-707 is a variant of recombinant human IL-2 that is pegylated at one site so that it blocks engagement of the high affinity IL-2 receptor alpha chain. This extends the half-life of the drug and increases tumor distribution and retention. richard harimanWebMay 26, 2024 · Conclusions: THOR-707 is a reprogrammed, site-directed, singly-pegylated rIL-2 that changes the pharmacologic profile of IL-2, potentially providing a favorable risk … red lights brian fallon lyricsWebMay 26, 2024 · Conclusions: THOR-707 is a reprogrammed, site-directed, singly-pegylated rIL-2 that changes the pharmacologic profile of IL-2, potentially providing a favorable risk-benefit profile. First-in-human studies are expected to begin this year evaluating THOR-707 as monotherapy and in combination with a PD-1 inhibitor. red lights by stray kidsWebJul 1, 2024 · Abstract. Aldesleukin is a recombinant form of IL-2 approved for metastatic melanoma and renal cell carcinoma that induced complete, durable remissions in certain … red lights by lvlyWebSince it cannot bind to IL2Ra expressed on innate lymphoid cells in the vascular endothelium, THOR-707 prevents IL-2-mediated recruitment and activation of eosinophils, and inhibits the induction of eosinophil-mediated vascular leak syndrome (VLS). Pegylation also extends the half-life of THOR-707. Compared to recombinant IL-2, THOR-707 allows ... richard harinck